Aurobindo Pharma gets USFDA nod for Cefadroxil Oral Suspension

26 Apr 2013 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cefadroxil for Oral Suspension USP 250mg/5mL and 500mg/5mL.

Cefadroxil for Oral Suspension USP, 250mg/5mL and 500mg/5mL is the generic equivalents of Warner Chilcott Company, Inc’s Duricef for Oral Suspension 250mg/5mL and 500mg/5mL. Cefadroxil is a cephalosporin antibiotic indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms such as urinary tract infections caused by E.coli, P.mirabilis, and Klebsiella species; skin and skin structure infections caused by staphylococci and/or streptococci; Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes.

The product has been approved out of Unit VI Cephalosporin formulations manufacturing facility in Hyderabad, India. The company now has a total of 187 ANDA approvals (160 Final approvals including 4 from Aurolife Pharma LLC and 27 Tentative approvals) from USFDA.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1171.40 9.55 (0.82%)
10-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×